STCube Completes Development of Immune-Oncology Small Molecule Drug in Collaboration with Georgetown University, USA
[Asia Economy Reporter Hyunseok Yoo] STCube announced on the 13th that it has developed a low-molecular compound drug of the immuno-oncology new drug substance STT-011 in collaboration with Dr. Stephen W Byers of Georgetown University in the United States.
According to the company, this substance was developed targeting proteins expressed in pancreatic cancer and other cancers. It is also said to be applicable to malignant tumors that have little effect or high mortality rates with existing chemotherapy or immunotherapy.
Dr. Stephen W Byers, who participated in the development of the substance, is a co-founder of Diviner Therapeutics, a U.S. company jointly conducting business with STCube, and a professor of oncology at Georgetown University.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- Suspended Sentence for Jung Yura on Fraud and Defamation Charges... Both Sides Appeal
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
A company official stated, “This new drug substance is developed as a low-molecular compound drug, making production easier and allowing administration to patients through various methods, which is expected to have great market potential. We have completed preclinical animal testing and plan to proceed with clinical trials in the future.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
